NCT06090227View on ClinicalTrials.gov

AMPK-activation by Metformin in FSGS: AMP-FSGS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

Metformin + Standard of Care

Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.

OTHER

Placebo + Standard of Care

Administration of daily placebo tablets with standard of care for 6 months.

Trial Locations (2)

10029

RECRUITING

Mount Sinai Hospital, New York

06510

RECRUITING

Yale New Haven Hospital, New Haven

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Yale University

OTHER